The Cambridge-born startup secured backing to scale its software stack and expand its London team.
"Big labs are currently betting that one model will rule them all. We think that’s wrong and our work proves this. Nature shows that real intelligence emerges from many systems working together. We’ve brought together incredible talent to enable a paradigm shift in how we build intelligent systems to solve real-world problems, with the infrastructure to make that possible, on any chip, anywhere in the world."
Wellington Management led the financing round, which brings total funding to £110m.
"Everyone is focused on building bigger models, but for physical AI, the bottleneck isn't model size. It's data readiness. You can have the most sophisticated model in the world, and it will still fail if the data feeding it is incomplete, inconsistent, or misaligned with real-world conditions. That's the problem we solve."
The funding will support Phase I clinical trials for the company lead antimicrobial candidate.
"We are extremely pleased to welcome the AMR Action Fund as a new investor. Their dedication to advancing the field of antimicrobials further reinforces our belief in the Alphamer platform as a transformative immunotherapeutic approach for addressing infections. This latest investment has enabled us a clear path to progress CTX-187 beyond Phase I trials and onto the development of a Phase II-ready asset. I would like to thank the AMR Action Fund, as well as all of our existing investors and collaborators, for their support."
Ventura Capital, GLG, and Sona AM led the financing round to support international growth and technology investments.
"Allica is a world-class business that is executing exceptionally well in a large, underserved market. Ventura is proud to be a major investor in Allica’s Series D, and we are ready to support this exceptional team’s next stage of growth into international markets."
